chadox1 ncov-19
VaccineexperimentalCOVID-19
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Jun 2, 2020 (NCT04536051)
Timeline
Indications
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04730895 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2021 | Damietta University, Kafrelsheikh University |
| NCT04973449 | Phase 2/Phase 3 (Phase 3) | Jun 27, 2021 | AstraZeneca |
| NCT04536051 | Phase 3 | Jun 2, 2020 | University of Oxford |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 1 | 1 | 1 | 2021 |
| Damietta University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Kafrelsheikh University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Oxford | Academic/Hospital | 1 | 1 | 1 | 2020 |
4 organizations
Page 1 / 1